Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects

Next Previous
X
Search
Trial Profile

A Multi-Center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary) ; Estradiol congener-compounds/progesterone congener compounds
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Amgen

    • Most Recent Events

    • 08 Apr 2019 Results assessing drug-drug interactions between Erenumab and an ethinylestradiol/norgestimate COC in healthy women published in the CNS Drugs
    • 11 Jun 2017 Results (n=22) presented at the 59th Annual Scientific Meeting of the American Headache Society.
    • 08 Jun 2017 According to an Amgen media release, the company will present data from this study at the 59th Annual Scientific Meeting of the American Headache Society 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top